Abstract
Introduction & Objective: Recent studies have shown that liver fat content (LFC) is associated with impaired glucose metabolism and insulin resistance in the obesity. It has been established that GLP-1RA could significantly reduce LFC in patients with T2DM. This study aimed to observe the effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity for 12 weeks, and further explore the correlation between abdominal fat content and glucose profiles.
Methods: This study recruited 71 obese patients (BMI≥28 kg/m²). All the patients have received liraglutide monotherapy for 12 weeks, and received anthropometric measurement, OGTT (Oral glucose tolerance test) and MRI examination at baseline and after 12 weeks treatment. The association between the glycemic metabolism and abdominal fat content was further analysed.
Results: After 12 weeks of liraglutide monotherapy, body weight in the obese participants decreased significantly (P=0.014). Fasting blood glucose (FBG), 2h postprandial blood glucose (2hPBG), HbA1c, HOMA-IR were remarkably improved (all P<0.001). TC and LDL-c were sharply reduced (P=0.004, P=0.027 respectively). LFC was strikingly more in subjects with impaired glucose regulation (IGR) group compared to those with normal glucose tolerance (NGT) at baseline (P=0.002). The decreased LFC in IGR group was significantly greater after liraglutide treatment than those with NGT (P<0.001). Linear regression analysis showed that HOMA-IR at baseline was the independent marker for LFC reduction after liraglutide treatment (B: 0.634; 95%CI:0.100-1.168, P=0.021).
Conclusion: Liraglutide monotherapy for 12 weeks significantly reduced LFC in patients with obesity. The LFC reduction may serve as one of possible mechanisms of blood glucose improvement in obese patients.
Disclosure
M. Du: None. J. Yue: None. Y. Qi: None. S. He: None. X. Lu: None. M. Yang: None. L. Wang: None. Q. Lu: None. J. Ma: None.
Publisher
American Diabetes Association